Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Discovery

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-17-1320PMID 29545369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• Multispectral imaging for highly accurate analysis of tumour‐infiltrating lymphocytes in primary melanoma

  2017cited by this paper
• Tissue adaptation: Implications for gut immunity and tolerance

  2017cited by this paper
• Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

  2017cited by this paper
• The Th17 Lineage: From Barrier Surfaces Homeostasis to Autoimmunity, Cancer, and HIV-1 Pathogenesis

  2017cited by this paper
• Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

  2017cited by this paper
• T-Lymphocyte Homing: An Underappreciated yet Critical Hurdle for Successful Cancer Immunotherapy

  2017cited by this paper
• Immunosuppressive enzymes in the tumor microenvironment

  2017cited by this paper
• Elements of cancer immunity and the cancer–immune set point

  2017cited by this paper
• Single-cell transcriptomics to explore the immune system in health and disease

  2017cited by this paper
• AACR Project GENIE: Powering Precision Medicine through an International Consortium.

  2017cited by this paper
• Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

  2016cited by this paper
• Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine

  2016influential reference
• Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.

  2016cited by this paper
• Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

  2016cited by this paper
• Multispectral Imaging of T and B Cells in Murine Spleen and Tumor

  2016cited by this paper
• Genomic Approaches to Understanding Response and Resistance to Immunotherapy

  2016cited by this paper
• Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

  2016cited by this paper
• Molecular and cellular insights into T cell exhaustion

  2015influential reference
• Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• PD-1/PD-L1 inhibitors.

  2015influential reference
• Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• A Wave of Regulatory T Cells into Neonatal Skin Mediates Tolerance to Commensal Microbes.

  2015cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• gCMAP: user-friendly connectivity mapping with R

  2014cited by this paper
• Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans.

  2014cited by this paper
• The Genotype-Tissue Expression (GTEx) project

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets.

  2013cited by this paper
• The immune contexture in human tumours: impact on clinical outcome

  2012cited by this paper
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012cited by this paper
• GATA3 controls Foxp3⁺ regulatory T cell fate during inflammation in mice.

  2011cited by this paper
• Balancing acts: the role of TGF-β in the mucosal immune system.

  2011cited by this paper
• Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus

  2009cited by this paper
• Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

  2005cited by this paper
• A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

  2005cited by this paper
• Dynamics of blood-borne CD8 memory T cell migration in vivo.

  2004cited by this paper
• Immunoregulation in the tissues by gammadelta T cells.

  2003cited by this paper
• Regulatory lymphocytes: Immunoregulation in the tissues by γδ T cells

  2003cited by this paper
• Abnormal T cell development in CD3‐zeta‐/‐ mutant mice and identification of a novel T cell population in the intestine.

  1993cited by this paper
• Lymphoid development in mice congenitally lacking T cell receptor alpha beta-expressing cells.

  1992cited by this paper
• Proliferative properties of murine intestinal intraepithelial lymphocytes (IEL): IEL expressing TCRαβ or TCRτδ are largely unresponsive to proliferative signals mediated via conventional stimulation of the CD3-TCR complex

  1991cited by this paper
• Cytotoxic differentiation of mouse gut thymodependent and independent intraepithelial T lymphocytes is induced locally. Correlation between functional assays, presence of perforin and granzyme transcripts, and cytoplasmic granules

  1991cited by this paper
• Proliferative properties of murine intestinal intraepithelial lymphocytes (IEL): IEL expressing TCR alpha beta or TCR tau delta are largely unresponsive to proliferative signals mediated via conventional stimulation of the CD3-TCR complex.

  1991cited by this paper
• lnterleukin-10-Deficient Mice Develop Chronic Enterocolitis

  year unknowncited by this paper

• Opportunities and challenges of targeting cGAS–STING in cancer

  2026cites this paper
• Cell membrane vaccine delivery system: A review of the recent advances against breast cancer.

  2025cites this paper
• Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattelite stable colorectal cancer.

  2025cites this paper
• Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts.

  2025cites this paper
• Tissue-specific tolerance mechanisms and lymph node co-drainage converge to shape T cell immunity in the upper digestive system and regulate pancreatic cancer progression

  2025cites this paper
• Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.

  2025cites this paper
• Protein post-translational modifications and tumor immunity: A pan-cancer perspective.

  2025cites this paper
• Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy

  2024cites this paper
• Impact of liver metastasis on immunotherapy in gastric carcinoma

  2024cites this paper
• Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles’ Biodistribution in Cancer

  2024cites this paper
• Organ-specific immune setpoints underlie divergent immune profiles across metastatic sites in breast cancer.

  2024cites this paper
• Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

  2024cites this paper
• Tissue specific tumor-gene link prediction through sampling based GNN using a heterogeneous network

  2024cites this paper
• Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis

  2024cites this paper
• Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer

  2024cites this paper
• Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer

  2024cites this paper
• Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns of acquired resistance to immunotherapy in patients with NSCLC.

  2024cites this paper
• Mechanisms driving the immunoregulatory function of cancer cells

  2023cites this paper
• Facts and hopes on biomarkers for successful early clinical immunotherapy trials: Innovative patient enrichment strategies.

  2023cites this paper
• Immunogenomics of cholangiocarcinoma.

  2023cites this paper
• Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer

  2023cites this paper
• Unfavorable tumor responses to immunotherapy in the liver: Lessons learned from clinical and preclinical studies

  2023cites this paper
• Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report

  2023cites this paper
• Modulation of T cell function and survival by the tumor microenvironment

  2023cites this paper
• Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis

  2023cites this paper
• Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa

  2023cites this paper
• PD-1/LAG-3 DYSFUNCTIONALITY SIGNATURES IN HUMAN CANCERS

  2023cites this paper
• The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.

  2023cites this paper
• Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer

  2023cites this paper
• Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer

  2023cites this paper
• Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies

  2022cites this paper
• Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression

  2022cites this paper
• Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

  2022cites this paper
• Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association

  2022cites this paper
• Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China.

  2022cites this paper
• Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis

  2022cites this paper
• Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?

  2021cites this paper
• Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer

  2021cites this paper
• Overcoming biological barriers to improve solid tumor immunotherapy

  2021cites this paper
• Tissue-resident memory T cells in tumor immunity and immunotherapy

  2021cites this paper
• Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation

  2021influential citation
• Promises and challenges of adoptive T-cell therapies for solid tumours

  2021cites this paper
• NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma

  2021cites this paper
• Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

  2021cites this paper
• Advancing to the era of cancer immunotherapy

  2021cites this paper
• Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

  2021cites this paper
• Toward personalized treatment approaches for non-small-cell lung cancer

  2021cites this paper
• IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.

  2021cites this paper
• Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments

  2021cites this paper
• Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression.

  2021cites this paper
• Pro- and Anti- Effects of Immunoglobulin A- Producing B Cell in Tumors and Its Triggers

  2021cites this paper
• Top 10 Challenges in Cancer Immunotherapy.

  2020cites this paper
• Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis

  2020cites this paper
• Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

  2020cites this paper
• Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges

  2020cites this paper
• Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes.

  2020cites this paper
• The cutting-edge progress of immune-checkpoint blockade in lung cancer

  2020cites this paper
• Primary and metastatic breast tumors cross-talk to influence immunotherapy responses

  2020cites this paper
• Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys.

  2020cites this paper
• Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response

  2020cites this paper
• Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer.

  2020cites this paper
• TIMER2.0 for analysis of tumor-infiltrating immune cells

  2020cites this paper
• A computational network approach to identify predictive biomarkers and therapeutic combinations for anti-PD-1 immunotherapy in cancer

  2020cites this paper
• Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.

  2020cites this paper
• Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

  2020cites this paper
• Preclinical murine tumor models: A structural and functional perspective

  2020cites this paper
• Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis

  2019cites this paper
• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

  2019cites this paper
• Development of a Microfluidic Droplet System for Immune Cell Multiplexing Experimentation

  2019cites this paper
• The melanoma microenvironment dissected through high throughput multiplexing: functional meaning of brisk/non brisk patterns and regression.

  2019cites this paper
• Impact des images radiologiques alvéolo-interstitielles pré-thérapeutiques sur le développement des pneumopathies induites par l’immunothérapie chez les patients atteints de cancer bronchique non à petites cellules

  2019cites this paper
• Tissue‐specific tumor microenvironments influence responses to immunotherapies

  2019cites this paper
• Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

  2019cites this paper
• Route of Infection Strongly Impacts the Host-Pathogen Relationship

  2019cites this paper
• A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

  2018cites this paper
• Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing

  2018cites this paper
• The Immune Landscape of Non‐Small‐Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures

  2018cites this paper
• Acquired resistance to immunotherapy in MMR-D pancreatic cancer

  2018cites this paper
• Combinations of Bevacizumab With Cancer Immunotherapy

  2018cites this paper
• World Journal of Gastrointestinal Surgery

  year unknowncites this paper